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Background: Previous reviews of geographical disparities in the prostate cancer
continuum from diagnosis to mortality have identified a consistent pattern of poorer
outcomes with increasing residential disadvantage and for rural residents. However,
there are no contemporary, systematic reviews summarizing the latest available
evidence. Our objective was to systematically review the published international
evidence for geographical variations in prostate cancer indicators by residential rurality
and disadvantage.
Methods: Systematic searches of peer-reviewed articles in English published from
1/1/1998 to 30/06/2018 using PubMed, EMBASE, CINAHL, and Informit databases.
Inclusion criteria were: population was adult prostate cancer patients; outcome measure
was PSA testing, prostate cancer incidence, stage at diagnosis, access to and
use of services, survival, and prostate cancer mortality with quantitative results by
residential rurality and/or disadvantage. Studies were critically appraised using amodified
Newcastle-Ottawa Scale.
Results: Overall 169 studies met the inclusion criteria. Around 50% were assessed as
high quality and 50% moderate. Men from disadvantaged areas had consistently lower
prostate-specific antigen (PSA) testing and prostate cancer incidence, poorer survival,
more advanced disease and a trend toward higher mortality. Although less consistent,
predominant patterns by rurality were lower PSA testing, prostate cancer incidence and
survival, but higher stage disease and mortality among rural men. Both geographical
measures were associated with variations in access and use of prostate cancer-related
services for low to high risk disease.
Conclusions: This review found substantial evidence that prostate cancer indicators
varied by residential location across diverse populations and geographies. While wide
variations in study design limited comparisons across studies, our review indicated that
internationally, men living in disadvantaged areas, and to a lesser extent more rural
areas, face a greater prostate cancer burden. This review highlights the need for a
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better understanding of the complex social, environmental, and behavioral reasons for
these variations, recognizing that, while important, geographical access is not the only
issue. Implementing research strategies to help identify these processes and to better
understand the central role of disadvantage to variations in health outcome are crucial to
inform the development of evidence-based targeted interventions.
Keywords: prostate cancer, rural, area-disadvantage, health disparity, systematic review, geographical variations,
continuum of care
INTRODUCTION
Worldwide, prostate cancer is the second most commonly
diagnosed invasive cancer and the fifth leading cause of cancer
deaths in men (1). Prostate cancer is especially prevalent
in developed regions including Australia, United States and
Western Europe, with incidence rates varying more than
25-fold between high and low incidence countries (1, 2). In
contrast, mortality rates are higher in less developed countries
especially among predominantly black Caribbean and sub-
Saharan African populations (1, 2). These wide variations in the
global burden of prostate cancer reflect the impact of country-
specific differences in Prostate Specific Antigen (PSA) testing
practices (2, 3), in addition to westernized diet, sedentary lifestyle
and obesity (2), genetic differences (2, 3), dissimilar health
systems, population life expectancy and competing causes of
mortality (4).
Wide and persistent geographical disparities in prostate
cancer incidence and mortality (5), treatment (6) and survival
have been identified globally (7). Our previously published
review (4) of international patterns in disparities along the
prostate cancer continuum from detection to incidence, staging,
treatment, survival and mortality identified a consistent pattern
of poorer outcomes with increasing residential disadvantage
and for rural residents. Specifically, men from rural and
socioeconomically disadvantaged areas had lower rates of
PSA testing, incidence, survival, and access or use of services,
but also more aggressive disease at diagnosis and higher
mortality rates (4). Although it is likely that the country-specific
factors mentioned above also contribute to these within-
country differences, a complex interplay of clinical, social,
environmental, and behavioral factors are probably also
involved (4–7).
Our earlier review (4) was limited in that it was not
systematic, considered only a limited number of reference
databases, and, given the extent of recent literature on this topic,
no longer provides a contemporary summary of international
patterns in prostate cancer. Here, we update and extend
this work by systematically reviewing current international
evidence on the extent of geographical variation in prostate
cancer outcomes, with a focus on patterns by rurality and
area-level socioeconomic disadvantage. Cancer outcomes along
the continuum from PSA testing to diagnosis to mortality and
survival are included. This review is intended to identify gaps
in knowledge, formulate strategic research priorities and inform
the development of evidence-based interventions to address
observed inequities.
METHODS
Patient Involvement
No patients were directly involved in the development of the
research questions, choosing the outcome measures of interest,
study design and implementation or interpretation of results.
Definitions of Geographical Measures
The studies included in this systematic review used a range of
definitions to define rurality and residential disadvantage. For
the purposes of this review, “urban” areas were those described
as “urban,” “metropolitan,” or “major cities,” with the remainder
being categorized as “rural” areas. Advantaged areas were those
described as “aﬄuent” or “advantaged,” with the remainder
being “disadvantaged.” Where studies reported on geographical
variations by intermediate categories, such as suburban
groups or quintiles of area-disadvantage, only comparisons
between most “extreme” rural and/or most disadvantaged to
the least rural and/or disadvantaged categories (such as very
remote vs. metropolitan and quintile one vs. quintile five), are
presented here.
Clinical Questions
This review was conducted according to published PRISMA
guidelines for conducting systematic reviews (8). Clinical
questions to guide the review were clearly defined following
a structured framework and agreed upon before commencing
the review process. The review addressed six key questions on
variations by residential location encompassing the key themes
of PSA testing, prostate cancer incidence, tumor characteristics,
survival, access to treatment services and prostate cancer
mortality (Table 1).
These themes and the relevant questions were repeated when
considering differences by residential disadvantage.
Literature Searches
The electronic databases: PubMed, EMBASE, CINAHL, and
Informit were systematically searched for all indexed articles
from 1 January 1998 to 30 June 2018. Final searches were
undertaken on 02 July 2018. The Web of Science database was
used for cited reference searches.
Search strategies were based on keywords and subject
headings to reflect the review aim (Supplemental File 1). Key
terms related to prostate cancer, e.g., “prostate neoplasms”;
and “prostate cancers” were combined with terms pertaining
to geographical aspects and area-based disadvantage, including
“geographic inequalities,” “spatial,” “health services accessibility”
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TABLE 1 | Clinical questions guiding the systematic review.
PSA testing
1. Internationally, do men living in more remote areas have lower rates of PSA testing for prostate cancer than men living in more urban areas?
2. Internationally, do men living in more socioeconomically disadvantaged areas have lower rates of PSA testing for prostate cancer than men living in more
affluent areas?
Prostate cancer incidence
3. Internationally, is there evidence of inequality in the incidence of prostate cancer according to rurality of residence?
4. Internationally, is there evidence of inequality in the incidence of prostate cancer according to socio-economic status of residence?
Tumor characteristics
5. Internationally, among men diagnosed with prostate cancer, do men living in more remote areas have more advanced tumor characteristics than men living in
more urban areas?
6. Internationally, among men diagnosed with prostate cancer, do men living in more socioeconomically disadvantaged areas have more advanced tumor
characteristics than men living in more affluent areas?
Prostate cancer survival
7. Internationally, among men diagnosed with prostate cancer, do men living in more remote areas experience poorer survival than men living in more urban areas?
8. Internationally, among men diagnosed with prostate cancer, do men living in more socioeconomically disadvantaged areas experience poorer survival than men
living in more affluent areas?
Access and use of treatment services
9. Internationally, among men diagnosed with prostate cancer, do men living in more remote areas access less prostate cancer-related treatment services than
men living in more urban areas?
10. Internationally, among men diagnosed with prostate cancer, do men living in more socioeconomically disadvantaged areas access less prostate cancer-related
treatment services than men living in more affluent areas?
Prostate cancer mortality
11. Internationally, do men living in more remote areas have higher mortality due to prostate cancer than men living in more urban areas?
12. Internationally, do men living in more socioeconomically disadvantaged areas have higher mortality due to prostate cancer than men living in more
affluent areas?
and “rural health”; and outcome measures of interest, such
as “PSA screening,” “incidence,” “stage,” “mortality,” “survival,”
“prostatectomy,” “brachytherapy,” and “therapy.” Additional
synonyms reflecting each of the key terms were also included.
Inclusion Criteria
Studies were eligible if they met the following inclusion criteria:
1) the population included adult male prostate cancer patients
or focused on a prostate cancer specific sub-group; and
2) the outcome measure was PSA testing, prostate cancer
incidence, stage at diagnosis, survival, access and use of
treatment services, or prostate cancer mortality
3) was a quantitative study on geographical differences by:
a) location of residential area (rural vs. urban, non-
metropolitan vs. metropolitan comparisons); and/or
b) socioeconomic status of residential location
The scope of the review was limited to English language peer-
reviewed original research articles. Reviews, editorials, books,
conference abstracts and commentaries were excluded, although
when identified through the systematic searches their reference
lists were examined for relevant articles.
Review Process
After removing duplicates, the titles and abstracts of all articles
generated by the queries were independently reviewed by two
reviewers (first PD, second PB) to assess their relevance to the
clinical question(s). Full text versions of all articles of potential
relevance were then retrieved for more detailed evaluation by one
reviewer (PD). During this process, articles were categorized as
“include” or “exclude” with reasons for exclusion being noted.
Critical Appraisal
The quality of all included articles was evaluated using pre-
defined criteria (9, 10). Quantitative studies were assessed
using a modified (11) version of the Newcastle-Ottawa
Scale (NOS) (10), a risk of bias assessment tool for non-
randomized studies. The NOS assesses cohort studies on
six items over five broad perspectives (a) selection bias; (b)
ascertainment of exposure and/or confounders; (c) outcome
assessment; (d) follow-up and (e) adjustments for residual
confounders (two items). Case-control studies are evaluated
on selection of cases and controls, ascertainment of exposure,
response rate, adequacy of case-definition and accounting for
residual confounders.
The NOS was further modified, by incorporating three
additional items evaluating (a) study attrition (missing
data), (b) statistical methods, and (c) data presentation,
based on published checklists (9). Studies were scored
according to the extent that they met each of the nine
assessed criteria (Supplemental File 2) using an ordinal
scale to rate the risk of bias as 0 (high), 1 (intermediate)
and 2 (low) and the individual item scores then summed
to give a total quality score. Each article was then assigned
a total score (range of 0–18) which was categorized as
“high” (12–16), “moderate” (9–13.5), or “low” (<9) quality.
Studies were not excluded based specifically on their
quality rating.
Studies were also classified according to the published
levels of evidence for quantitative observational studies
from the Australian National Health and Medical Research
Council (NHMRC) (17) in decreasing order of strength
as Level I, Level II, Level III-1, Level III-2, Level III-3
or Level IV.
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FIGURE 1 | Process of inclusion and exclusion of studies for the systematic review.
Data Extraction
Information on study features including bibliography (author(s),
year, title), setting, time period, design, population (such as
sample size, eligibility criteria), outcome measures, assessed
geographical unit(s), measure used to define urban/rural
residence and/or area disadvantage (if applicable), relevant
statistical results and key findings were extracted from all
included articles by one reviewer. A selection of these were
randomly checked by another reviewer. Disagreements were
resolved by discussion until consensus was reached. Any
discrepancies were rechecked with the original source.
RESULTS
Study Selection
The process of identifying relevant articles for the review is shown
in a PRISMA diagram (Figure 1). A total of 2,568 articles were
identified across combined databases with another 54 citations
found through other sources (citation searches, reference lists,
other reviews) After removing duplicates, 1,418 articles remained
of which 1,015 were excluded after initial scanning of the
title/abstracts. Following assessment of the remaining 403 full-
text articles, 169 met the inclusion criteria for the review. Of the
234 excluded articles, most (more than 95%) did not specifically
present quantitative statistics on geographical variations in the
outcomes of interest, and/or used only individual-level instead of
area-level measures of socioeconomic disadvantage.
Study Characteristics
Around half (18) of the included studies were from the
United States (USA), followed by Australia (19), the
United Kingdom (UK, 24), Canada (5), Spain (4), the
Netherlands (3), New Zealand (3), Denmark (2), France
(2), and Ireland (2). Seven more studies were also from Europe
(one each from Belgium, Finland, Germany, Greece, Lithuania,
Sweden, and Switzerland), five from Asia (two from Japan, one
each from Iran, South Korea and Taiwan), two from other parts
of North America (French West Indies, Puerto Rico), one from
South America (Colombia), one from Africa (Egypt) and one
including Australia and Canada (Supplemental File 3).
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Data for 157 (93%) of the included studies were sourced
from administrative collections, such as population-based state
or national cancer registries, official census and mortality records
or non-population based clinical databases. The remaining 12
studies involved medical record reviews and cross-sectional
surveys. With respect to study design, the majority (160, 95%)
were observational cohort studies, eight were cross-sectional and
one was a case-control study.
Of the 169 studies, 46 reported rural/urban differences in
at least one of the outcome measures of interest, 82 assessed
variations by residential disadvantage while 41 assessed both
these measures. Overall, 87 studies looked at differences by
residential rurality and 123 by disadvantage, respectively. Studies
varied widely in the definition of urban or rural residence. While
more than half (62%) of the relevant 87 studies used standardized
definitions, such as the USA Department of Agriculture’s Rural
Urban Continuum Codes (RUCC) and Rural Urban Commuting
Area Codes (RUCA) (12, 20) or the Accessibility/Rurality Index
of Australia (ARIA+) (13) others defined non-urban and urban
areas based on distances to services, degree of urbanization,
population size or density. Three studies did not provide detailed
information regarding how the geographical classification was
derived (Supplemental File 3).
A range of measures were also used to define residential
disadvantage (Supplemental File 3). More than three-quarters
(76%) of the 63 non-USA-based studies used a standardized
definition, such as the Australian Index of Relative Socio-
Economic Disadvantage (IRSD) (14), Scottish Index of Multiple
Deprivation (SIMD) (15), French Deprivation Index (16), or the
UK-based Index of Multiple Deprivation (IMD) (21), Carstairs
(22), or Townsend Deprivation Indexes (23). Of the 60 USA-
based studies, 36 (60%) used various area-based indicators
including median income, education or poverty while the
remaining 24 studies created study-specific composite scores
derived from these area-based measures.
Around half (24) of all the included studies were graded as
high quality and the remaining 85 as moderate quality. There
were no studies assessed as low quality. The median quality score
was 13.4 (interquartile range of 12–15). Contributing to this
higher quality was that most studies (138, 82%) used population-
based representative data sources, such as cancer registries and
mortality records. The key limiting factors were that 31 (18%)
studies did not use a population-based representative sample,
while more than a third (61, 36%) did not adjust for confounders
or presented only age-adjusted estimates by residential location.
Although cancer registries and mortality databases provide
representative, reliable and objective data, they present limited
information on all plausible prognostic factors. The lack of
information on the extent of follow-up also lowered study quality.
No study provided Level I evidence, nearly three-quarters (71%)
gave Level II evidence, one quarter (24%) Level III evidence and
5% Level-IV evidence (Supplemental File 3).
Key Findings
Studies are summarized below (Figures 2–5; Tables 2–7)
according to clinical questions within each of the key themes: (1)
PSA testing, (2) incidence, (3) tumor characteristics, (4) survival,
(5) access and use of services, and (6) mortality outcomes.
Within each clinical question, results are presented separately
for variations by rurality and residential disadvantage, further
grouped by country within each of the continents (Africa,
Americas, Asia, Europe and Oceania). Since several studies
reported on multiple outcomes, some studies are repeated either
in the same table or across multiple tables.
When multivariate analyses were conducted (136 of 169
studies), only the fully adjusted estimates are reported because
many such studies only reported those results. Given the
wide heterogeneity among studies in terms of the definitions
of geographical measures, time periods, study populations,
statistical methods and data presentation, only general trends
within and among studies as well as between andwithin countries
have been described. Given these limitations, any summary
patterns have been deliberately interpreted with caution. The
emphasis is on describing whether there was evidence of
geographical variations in the relevant outcome by the reported
measure of rurality and/or disadvantage, and if so, the direction
and magnitude of the effect.
PSA Testing
Rurality
Results were not consistent across the 11 included studies
(Figure 2; Table 2), both within and between countries. All
studies included men aged at least 40 years. Based on the 2012
Behavioral Risk Factor Surveillance System (BRFSS) survey, two
studies from the USA (one high, one moderate quality), both
reported that asymptomatic non-Hispanic white men from rural
areas were 11% more likely to undergo PSA testing than those
from urban areas, although the geographical differences were
not significant among other ethnic groups (26, 27). While urban
residence was associated with lower prevalence of PSA testing in
a high quality cross-sectional study using the 2010 BFRSS survey
(19), the reverse pattern (higher PSA testing in urban areas) was
reported by an earlier moderate-quality study, based on the 2001
BRFSS survey (25). Men from urban areas were also more likely
to have repeated PSA tests within 3 years in another USA-based
moderate quality study (28).
A moderate quality study from the UK found no differences
by urban/rural location in PSA testing (23), while three other
(moderate quality) studies reported higher rates of PSA testing
among men from urban areas in Australia (31, 32) and New
Zealand (33). Consistent with this, urban residents were 10%
more likely to have ever had PSA testing and 20% more likely
to have been tested within the past 2 years from 1992 to 2012 in
Switzerland (30), while men living in regions with higher ratio of
specialists to general practitioners (GPs) were around eight times
more likely to have PSA testing in Canada (29) (both studies
moderate quality).
Residential disadvantage
All four (two high, two moderate quality) of the included studies
reported that PSA testing was more common in aﬄuent areas
(Figure 2; Table 2). Among 212,039 men aged 40–69 years in
the UK, men living in most disadvantaged areas were 16% less
likely to have a PSA test between 2006 and 2010 than those from
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FIGURE 2 | Summary of key patterns by residential rurality for PSA testing, prostate cancer incidence, disease spread, mortality, overall, and net survival.
FIGURE 3 | Summary of key patterns by residential disadvantage for PSA testing, prostate cancer incidence, disease spread, mortality, overall, and net survival.
aﬄuent areas (23). Similar patterns were reported by one Scottish
(35) and two Canadian studies (29, 34).
Incidence
Rurality
Of the 23 studies included, 14 (six high, eight moderate quality)
reported higher prostate cancer incidence rates in urban areas
(25, 32, 36, 38, 40–44, 46, 47, 49, 52, 53), two (moderate) higher
rates in rural areas (50, 55) and seven (one high, six moderate)
no urban rural differences (31, 37, 39, 45, 48, 51, 54) (Figure 2;
Table 3). Six studies used a mixture of data collected both prior
to and after the widespread use of PSA testing, which combined
with varying time-periods for analysis, could lead to conflicting
patterns (31, 32, 39, 49, 51, 55).
While eight of the USA-based studies, reported higher
incidence rates among urban residents (or those from areas
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FIGURE 4 | Summary of key patterns by residential rurality for access and use of prostate cancer related services.
FIGURE 5 | Summary of key patterns by residential disadvantage for access and use of prostate cancer related services.
with higher density of urologists) (25, 38, 40–44, 46), two found
no geographical differentials (39, 45). Similarly, two Australian
studies reported no significant differences (31, 54), three studies
found higher prostate cancer incidence among urban males
(32, 52, 53) and one study recorded the reverse pattern (55).
In Denmark, urban men had higher incidence rates from
1994 to 2003 (47), but no differential was evident from 2004
to 2008 (48).
Residential disadvantage
Prostate cancer incidence was consistently higher among men
from aﬄuent areas across 25 (11 high, 14 moderate quality) of
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the 30 included studies with only a single (moderate) USA-based
case-control study reporting the reverse pattern (66) (Figure 3;
Table 3). The remaining four (two moderate, two high quality)
studies from the USA (57), UK (51), Japan (70), and FrenchWest
Indies (67) found no differentials by residential disadvantage.
Analysis of the 1988–1992 Surveillance, Epidemiology, and
End Results (SEER) data showed that residents of aﬄuent areas
had higher prostate cancer incidence than men from deprived
areas (60), while rates decreased monotonically with increasing
residential disadvantage in the USA from 2005 to 2009 (56).
Similar patterns were reported by nine other USA-based (41, 46,
58, 59, 61–65), 11 European, (15, 16, 35, 48, 49, 71–76) and one
study each from Australia (53), Puerto-Rico (68), and Iran (69).
Tumor Characteristics
There were some variations in the definition of advanced prostate
cancer with three studies each basing their classification on tumor
size (77, 78, 85) or prostate cancer risk groups (79, 86, 100)
and one on pathological Gleason score (90). All remaining
studies used a standard cancer staging system (such as the SEER
Summary stage or TNM) with Stage I-II cancers consistently
referred to as localized disease, Stage III as regional disease and
distant/metastatic (Stage IV) cancers as advanced (18, 24, 25, 39,
58, 64, 84, 88, 92, 102), although some collectively categorized
both regional and distant cancers as advanced disease (21, 41, 55,
80–83, 87, 89, 91, 93–99, 101).
Rurality
Findings were not consistent across the 16 included studies
(Figure 2; Table 4), with nine (four high, five moderate quality)
reporting more advanced tumor characteristics among rural men
and six (three high, threemoderate) no geographical differentials.
However, one high quality study from New Zealand found that
men who lived closer to cancer centers were more likely to
have advanced disease (87). There were no clear patterns in
study findings with characteristics, such as sample size or time
period.While three Australian studies (83–85) found no evidence
of geographical differentials, three others reported that rural
men were more likely to be diagnosed with advanced disease
(24, 55, 86). Further discrepancies in findings were evident across
the nine USA-based studies, with six reporting more advanced
disease among rural residents (25, 77, 81, 82) and those with
poorer access to urologists (41, 79), whereas three others found
no significant differences in the rates of advanced disease between
urban and rural men (39, 78, 80).
Residential disadvantage
A consistent pattern of advanced stage at diagnosis among men
from disadvantaged areas was evident across 21 (15 high, six
moderate quality) of the 25 included studies (Figure 3; Table 4)
despite varying definitions of advanced prostate cancer. Four
studies (two high, two moderate), three from the USA (41, 80,
97) and one from New Zealand (87) found no differences by
residential disadvantage.
Analysis of 436,251 incident cases from the USA found that
males from disadvantaged areas were 1.27 times more likely
to be diagnosed with advanced prostate cancer from 2005 to
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2009 (88). Similar patterns were reported by 12 other USA-
based studies (18, 58, 64, 82, 89–96), although the differential
was only evident after 1987 in one instance (64) and among
men aged 50–74 years at diagnosis in another study (58). All
three studies from Australia (24, 84, 102), four from the UK
(21, 99–101), and the single Dutch study (98) also reported
positive association between residential disadvantage and being
diagnosed with advanced disease.
Survival
Any interpretation of patterns and comparability across studies
should reflect the type of survival measure used and their
respective definitions. Two commonly used measures are overall
survival (deaths from all causes) or net survival (includes relative
and cancer-specific survival) that is the mortality specifically
associated with a cancer diagnosis (186). Patterns are presented
separately for overall and net survival.
Rurality
Of six studies that looked at association between residential
rurality and overall survival (Figure 2; Table 5), four (high
quality) reported no geographical differentials for men diagnosed
with prostate cancer in the USA after controlling for treatment
and comorbidities (103–106). Similar patterns were reported by
a single (moderate quality) Australian study (108) whereas men
living closer to primary care had higher survival in a single
(high quality) study from England that did not control for either
treatment or comorbidities (107).
However, all four moderate quality studies, one from
Denmark (47) and three from Australia (31, 55, 109) that
reported poorer prostate cancer relative survival (excess
mortality risk of 1.14–2.53, rural vs. urban) for rural residents
did not consider comorbidities or treatment, although two
did adjust for stage at diagnosis (55, 109). Four (high quality)
studies, two Australian (85, 113), and one each from Scotland
(112) and Sweden (111) also found consistently lower prostate
cancer survival among rural residents. Only one of these studies
adjusted for comorbidities (111), two for stage (85, 113) and
none for treatment. However, three other studies (one high, two
moderate quality), from Australia (114, 115) and the USA (110)
found no significant associations with rurality for stage-adjusted
estimates. Of the 11 papers in total that reported net survival
(relative or prostate-cancer specific survival), only three found
no geographical differentials in survival and eight higher survival
among urban men (Figure 2; Table 5).
Finally, most of the 17 included papers focused on medium
term survival with two reporting survival 10-years after
diagnosis (55, 85).
Residential disadvantage
A consistent pattern of poorer overall survival among men
diagnosed with prostate cancer while living in disadvantaged
areas of the USA was evident across eight (seven high,
one moderate quality) (103–106, 116–119) studies (Figure 3;
Table 5). Four more studies (three high, one moderate quality),
one each from Ireland (120), England (107), Australia (108),
and the Netherlands (98) (only among men aged 60–74
years with localized or 60+ years with advanced disease) also
reported similar patterns even after adjustment for various
combinations of potential explanatory factors, notably stage,
treatment and comorbidities (98, 103–106, 108, 116–120). Only
one USA-based (high quality) (89) study found no differences by
residential disadvantage.
Fifteen studies (seven high, eight moderate quality) reported
lower prostate cancer relative survival rates for residents of
disadvantaged areas even after adjusting for stage (55, 127, 134)
although none controlled for treatment or comorbidities. Six
studies were from the UK (22, 126, 127, 129, 131, 132), three
from Australia (55, 133, 134) with one each from Colombia
(122), France (124), Germany (125), Japan (123), New Zealand
(136), and the USA (121). Although the gap in 1-year relative
survival for men with prostate cancer from most and least
disadvantaged areas in England had narrowed between 1996 and
2013, significant socioeconomic inequalities remained (131, 132).
However, two other high quality UK-based studies (128, 130) and
one Australian study (moderate quality) (135) found no evidence
for differentials in relative survival by residential disadvantage.
Finally, 14 (nine high, five moderate quality) of 18 included
studies consistently reported poorer prostate-cancer specific
survival among males from disadvantaged areas in the USA
(nine studies) (59, 60, 93, 110, 137–141), Australia (two studies)
(102, 113), Netherlands (142), Sweden, (111), and Scotland
(112) after controlling for diverse explanatory factors. On
multivariate analyses, estimated hazard ratios (HR) for increased
risk of mortality (poorer survival) ranged from 1.16 to 2.37
(disadvantaged vs. aﬄuent). Three of the four remaining studies
(two high, two moderate quality) found no evidence for
survival differentials by residential disadvantage in Japan (70),
New Zealand (87) and Australia (85) while another Australian
study reported that although residential disadvantage was not
significantly associated with prostate cancer mortality, male
residents of those areas had poorer non prostate-cancer specific
mortality (114).
In summary, of 49 included studies, male residents of
disadvantaged areas had consistently poorer overall (12 of 13)
and net survival (29 of 36) (Figure 3; Table 5) when diagnosed
with prostate cancer.
Most studies focused onmedium-term survival, with only two
(55, 85) following men for longer than 10 years after their cancer
diagnosis. Four presented 1-year survival estimates (112, 131,
132, 142).
Access and Use of Services
Treatment of early stage prostate cancer, localized disease
or National Comprehensive Cancer Network (NCCN) low
to intermediate-risk groups remains controversial with no
consensus regarding their optimum management (187, 188).
Several treatment types are available depending on clinical
features, patient age and preferences. For example, men
diagnosed with localized (defined as no identifiable regional
lymph nodes or distant metastases) disease have three main
options: expectant management (EM) that is monitoring for
cancer progression while not having curative therapy, curative
surgery typically radical prostatectomy (RP) or radiotherapy
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(RT), such as brachytherapy (BB) or external beam radiotherapy
(EBRT). As such, patterns described below for different
treatment types do not necessarily imply adverse outcomes by
residential location.
For ease of interpretation we have presented patterns below by
different treatment types (Figures 4, 5; Table 6) after an overall
summary. No studies reporting geographical variations in use of
services for metastatic disease were found.
Rurality
Twenty-two (11 high, 11 moderate) out of 28 included studies
reported geographical variations in access and use of services
among men diagnosed with prostate cancer with six (four high,
two moderate quality) finding no differences.
Expectant management. While men living furthest away from
treating facilities were 8% less likely to have expectant
management for very low-risk prostate cancer in the USA from
2010 to 2013 (143), an earlier study reported no differences by
residential rurality for localized disease (144).
Radical prostatectomy. Patterns for RP varied with two USA-
based (44, 77) and five Australian studies (31, 32, 115, 147, 148)
reporting higher rates among urban men or those living closer to
major treatment facilities (148). Whereas, two other studies from
the USA (144, 145) as well as one each from Australia (108) and
England (146) reported no geographical differentials.
Radiotherapy. Included studies gave mixed results for
differentials in RT rates for localized or early stage prostate
cancer in the USA, with two finding no significant differences
(144, 145), one higher rates of BB among rural (77) and one
among urban residents (44). Rural men were also 83% less
likely to receive intensity-modulated RT (IMRT) for localized
prostate cancer (149). Increasing distance from radiation centers
in England was associated with lower RT among men diagnosed
with prostate cancer (146), while in Australia RT rates were
higher among urban than rural males (150).
Type of curative treatment. A study from South Korea (153) and
two from the USA (151, 152) found no association between
residential rurality and the type of curative treatment received
(i.e., RP vs. RT). Moreover, among men with early stage prostate
cancer who underwent curative treatment in the USA, urban
and rural residents were about equally as likely to receive a
one-time treatment (RP or BB) (77), whereas urban residence
was associated with greater use of one-time RP or BB rather
than daily EBRT for localized disease in another study (44).
However, there was no difference by residential location in the
use of combined radiotherapies (EBRT and BB vs. EBRT) for
intermediate or high-risk disease (116). Urban men were more
likely to undergo cryotherapy for localized disease in a single
USA-based study (154).
Any curative treatment. Findings from the USA indicated that
rural men were 19 to 25% less likely to receive any curative
treatment for localized (151) or early-stage (77) disease, whereas
a single state-based study found no geographical differences in
receipt of curative treatments for localized disease in Wisconsin,
USA (152). However, rural residents were more likely to undergo
treatment than active surveillance for very low-risk disease (155).
Finally, urbanmenwere around two timesmore likely to undergo
curative treatment in one Australian study (86).
Hormone therapy. A consistent pattern of no geographical
differentials in hormone therapy (HT) was reported by two USA-
based (78, 144) and one South Korean study (153), although
in Australia rural men were 36% more likely to undergo
orchiectomy (147).
Quality of care. Although one USA-based study found that
urban men were more likely to be treated at comprehensive
care facilities, no geographical differentials were evident in
the timeliness or quality of their care except for receipt of
recommended RT dosage (78). Urban residents were more likely
to be treated for high-risk disease at academic centers in the
USA (156) and by high-volume surgeons or private hospitals in
Australia (85).
Access to care. Two USA-based studies reported poorer access to
treatment centers among rural men (78, 106), while in Australia,
improving access to RT facilities increased its uptake among rural
prostate cancer patients (159). Finally, rural residents were more
likely than their urban counterparts to undergo prostate cancer-
related treatment at larger more comprehensive RT facilities
(157) or established centers for robotic surgery rather than
nearest facilities (based on travel times) in England (158).
Residential disadvantage
A clear and persistent pattern of variations in the access and use
of prostate cancer related services by residential disadvantage was
evident across 24 (11 high, 13 moderate quality) of 27 included
studies with three (high quality) reporting no difference.
Expectant management. One USA-based study found that
residents of aﬄuent areas (vs. disadvantaged) with low-risk
disease were two times more likely to be under active surveillance
(a strategy of close monitoring, with intent of curative treatment
on disease progression) than watchful waiting (monitoring and
treating symptoms with palliative intent) (160). By contrast one
study from the UK (100) and one from the Netherlands (98)
reported that men aged below 60 years from disadvantaged areas
were more likely to be under expectant management for low-risk
or localized disease, respectively.
Radical prostatectomy. Four studies from the USA reported that
residents of aﬄuent areas had higher rates of RP for localized
(144, 145), intermediate-risk (104) and non-metastatic prostate
cancer (162), while one found no differences (161). Men from
disadvantaged areas were consistently less likely (range 17–44%
vs. aﬄuent) to undergo RP in the UK (four studies) (99, 100, 146,
163), Australia (two studies) (108, 147) and the Netherlands (98).
Radiotherapy. Higher residential advantage was consistently
associated with greater RT usage (OR 0.32–0.85 disadvantaged
vs. aﬄuent) in the USA (145, 162) and UK (99, 146, 163) with
one USA-based study finding no differences (161). Males from
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aﬄuent areas in the USA were more likely to receive IMRT
for localized disease (149). However, rates of adjuvant RT after
surgery did not vary by residential disadvantage in one USA-
based (164) and one Canadian study (165).
Type of curative treatment. While one study found that men
from disadvantaged areas were less likely to receive RT than
surgery for localized prostate cancer in the USA (166), another
found no significant differentials by residential disadvantage
(167). However, aﬄuent residents had higher usage of combined
EBRT and BB (vs. EBRT) for intermediate or high-risk disease
(116) and were more likely to undergo BB than cryotherapy for
localized disease (154). In the Netherlands, men aged 60–74 from
aﬄuent areas were significantly more likely to have one-time BB,
whereas higher receipt of EBRT was associated with living in
disadvantaged areas, for those aged below 60 years (98).
Any curative treatment. A consistent pattern of men living in
disadvantaged areas being 13 to 40% less likely to receive curative
treatment when diagnosed with prostate cancer of varying stage
or risk group was evident across five studies from the USA
(77, 89, 155, 167, 168) and one from England (163).
Hormone therapy. By contrast, residents of disadvantaged areas
had higher rates of HT in three studies from the USA (89, 161,
168) and one each from England (163) and Australia (147) with
no differentials found in the Netherlands (98). One USA-based
study found no association between residential disadvantage
and secondary HT after primary curative treatment for non-
metastatic prostate cancer (169).
Access to care. Men from aﬄuent areas were more likely to
travel beyond their closest treatment centers to larger established
centers in England especially those offering robotic surgery
(158) or innovative radiation therapies, such as IMRT or proton
beam therapy (157). Finally, there were no differences in post-
surgery referral rates to radiation oncologists for high-risk
disease between aﬄuent and disadvantaged areas in Ontario,
Canada (165).
Prostate Cancer Mortality
Rurality
Eleven (five high, six moderate quality) of the 18 included
studies consistently reported higher prostate cancer mortality
rates among rural residents (25, 31, 32, 45, 172–177, 181),
one (moderate) the reverse trend (179) and four (one high,
three moderate quality) no differences (171, 178, 180, 182)
(Figure 2; Table 7). A (high quality) study by Lagace et al.
(170) found higher prostate cancer mortality rates among
rural men in Canada and a trend toward higher death
rates in rural areas for Australia. Another high quality
study also reported higher prostate cancer mortality rates
outside urban areas in Australia, although the difference
between most extreme remote and urban category was not
significant (52).
In the USA, men from rural areas had 3–15% higher
prostate cancer mortality rates than those from urban areas
across four studies (25, 45, 176, 177) with four more
reporting similar patterns (172–175). Although the study
by Zhand et al. (178) found no rural urban differences
in prostate cancer mortality rates in the Mississippi Delta
region, both urban and rural rates were higher compared
to corresponding urban and rural areas for other regions in
the USA.
Residential disadvantage
Five (two high, three moderate quality) (62, 174, 177, 178, 184) of
the seven included studies from the USA reported higher prostate
cancer mortality rates in disadvantaged areas with two (high
quality) (173, 183) reporting no difference (Figure 3; Table 7).
By contrast, all six studies (two high, four moderate) from other
countries, one each from Puerto Rico (68), Japan (70), Belgium
(180), Finland (72), Spain (185), and Scotland (35) reported no
difference. A noteworthy point is that the significantly higher
prostate cancer mortality rates among disadvantaged men in
Texas between 1996 and 2004 reported by Wan et al. (184)
only held for the smaller census block groups and tract-level
geographical units of the USA-census, with the effect reversing
for larger county-level areas.
Effects of Rurality After Adjustment for
Residential Disadvantage
Of the 169 articles included, 34 (20%) presented estimates of
rurality, adjusted for residential disadvantage, for at least one of
the considered outcomes. The proportion of studies including
these adjusted estimates varied for each outcome, ranging from
11% (2 of 18) for prostate cancermortality, 18% for PSA testing (2
of 11) and prostate cancer incidence (4 of 23), 31% for spread of
disease (5 of 16), 36% for access and use of services (10 of 28), 65%
for net survival (7 of 11) and 100% for overall survival (6 of 6).
The majority of the studies including adjusted estimates
were from the USA, followed by Australia and Canada
(Supplemental File 4). However, there was wide heterogeneity
across studies in the covariates included in the statistical models;
this does limit comparisons across them. In addition, only two
studies presented both unadjusted and adjusted estimates by
rurality, hence we cannot reliably assess the effect of rurality
after controlling residential disadvantage. Nevertheless, after
adjustment for residential disadvantage, there was a consistent
pattern for rurality to remain independently associated with
geographical variations in prostate cancer incidence, net survival
and access to services (Figure 6), and for no independent
association with overall survival. There were no consistent
patterns for PSA testing, mortality or advanced spread of disease.
Overall, for most outcomes except advanced spread of disease
and prostate cancer mortality, there appeared to be more
consistent evidence of an independent effect for residential
disadvantage than for rurality (Figure 7).
In summary, included studies did not provide sufficient
evidence to conclude that the urban/rural differential in prostate
cancer outcomes was completely accounted for by disparities
in residential disadvantage. However, there is a suggestion that
residential disadvantage may have a stronger effect on prostate
cancer disparities than living in an urban or rural area.
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FIGURE 6 | Summary of key patterns by rurality from studies that also adjusted for residential disadvantage.
FIGURE 7 | Summary of key patterns by residential disadvantage from studies that also adjusted for rurality.
DISCUSSION
This systematic review found a consistent pattern of differences
by residential disadvantage across the prostate cancer continuum
from PSA testing to incidence, staging, treatment, survival and
mortality. Specifically, compared to residents of aﬄuent areas,
men living in socioeconomically disadvantaged areas generally
had lower PSA testing and prostate cancer incidence, more
advanced spread of disease at diagnosis, poorer survival, and
higher mortality. Findings by rurality were less consistent. Where
a pattern was observed, it was that men from rural areas had
lower PSA testing, incidence and survival, more advanced disease
and higher prostate cancer mortality than urban residents. There
was also evidence that men from more rural or disadvantaged
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areas had poorer access and use of prostate cancer-related
treatment services than those from urban or advantaged areas.
Although the underlying reasons for these variations are not
known, there is widespread consensus that they reflect complex
and interacting social, genetic, environmental and behavioral
processes that can occur at a range of geographical scales (7,
189). The finding that some observed geographical patterns
varied by ethnic status, such as with PSA testing for rurality
(26, 27), incidence by area disadvantage (41, 46), while others
were consistent, such as incidence by rurality (46) highlights the
likely complexity of these processes.
Prostate cancer incidence rates increased sharply with the
dissemination of PSA-based testing in the early 1990s (5, 190).
It is likely that some of the observed geographical patterns in
prostate cancer incidence and survival may reflect geographical
variations in PSA testing prevalence. Specifically, men from
urban (25, 28–33) and aﬄuent (23, 29, 34, 35) areas had higher
PSA testing rates than those from rural or disadvantaged areas,
respectively. This has been suggested to be due to differential
access to screening services and health care (26, 27, 29, 30),
GP attitudes (27, 30, 33, 34), health literacy (26–28, 30), socio-
cultural norms (26, 27), and help-seeking behaviors (26–28, 30).
There was widespread agreement that the higher prostate cancer
incidence (15, 16, 31, 39, 41, 42, 47, 48, 53, 56, 62, 68, 73, 76)
and lower advanced stage diagnoses (21, 24, 25, 84, 86, 88)
among urban and aﬄuent men reflected increased detection of
localized and latent cancers through PSA testing. The impact of
PSA testing on prostate cancer mortality risks however remains
controversial (2, 191). Variations in potential risk factors and
health behaviors reflecting physical and social environment (35,
36, 47–49, 56, 60, 62, 125, 177, 180), health care quality, access
or utilization (24, 62, 68, 71, 80, 177, 180) and availability of
specialists (41, 79, 174) were other commonly cited reasons for
the geographical disparities in prostate cancer incidence, stage
and mortality.
Non-clinical factors that have been suggested to contribute
to geographical patterns of care include differences in access to
and availability of treatment modalities (77, 85, 151, 153, 157,
158), clinician practice patterns (86, 108, 116, 145, 151, 153,
162), patient preferences (77, 86, 98, 108, 151, 153, 155, 162),
comorbidities (77, 98, 99, 116, 161, 162), and treatment decision-
making processes (98, 99, 161, 162). Variations in treatment could
also potentially reflect the managing physician’s preferences (99,
161, 192) which, in the absence of a definitive treatment guideline
for prostate cancer, strongly influences prostate cancer treatment
choices (99, 192, 193).
Although stage at diagnosis impacts prostate cancer survival
(60, 89, 125, 127), survival differentials by residential location
were evident even after adjustment for stage (55, 85, 93, 102,
110, 113, 127, 134, 137, 138, 140), and in some instances also
adjusted for treatment (137, 138, 140). Many of the proposed
explanations for the geographical variations in survival were
multifactorial and included variations in psychosocial factors
(93, 98, 105, 108, 111, 113, 117), comorbidities (98, 104, 113, 125,
126, 135, 139, 142), access to high-quality healthcare (55, 60, 93,
98, 103, 104, 106, 107, 110, 113, 117, 125, 127, 135, 139, 141),
intensity of clinical follow-up (55, 102, 127, 139), and compliance
with recommended treatments (47, 106, 125). Finally, even after
adjusting for stage, there is likely to be a residual confounding
by PSA testing, in that the observed survival differentials may
reflects the diagnosis of latent prostate cancers through PSA
testing rather than a true difference in survival (194).
It is likely that inequalities in access to diagnostic and
treatment services is a key factor contributing to the geographical
disparities in prostate cancer outcomes. These inequalities are
influenced by socioeconomic factors, health care policies and
proximity to medical services. For rural residents, a diagnosis
of prostate cancer can present unique challenges in obtaining
appropriate, high-quality care, including limited local services
and long travel distances incurring financial, psychosocial and
logistical barriers (195–197). Several of the studies in this review
found that increasing travel burden impacted treatment (116,
143, 146, 150, 159, 166). Moreover, high-volume specialists
and hospitals which have been associated with rapid adoption
of innovative treatments and technologies (149, 158, 196),
multidisciplinary care (103, 143, 165) and better prostate
cancer-related clinical outcomes (103, 106, 198) are typically
concentrated in urban areas (196, 199). The close overlap
between rurality and residential disadvantage in countries, such
as Australia (85, 195) and the USA (77, 200) and the necessity
for repeated visits for specific treatments like EBRT are likely to
worsen the impact of accessibility-related barriers.
From the studies that reported results adjusted for both area
disadvantage and rurality, there was consistent evidence that the
strong impact of residential disadvantage remained even after
adjusting for rurality. While its effect was diluted, it appears
that the urban/rural differential in prostate cancer outcomes
was not completely accounted for by disparities in residential
disadvantage. Therefore, living in rural areas constitutes an
additional disadvantage in terms of prostate cancer outcomes,
over and above residential socioeconomic disadvantage itself. As
such, rather than considering these two geographical measures
separately, both rurality and socioeconomic disadvantage need
to be considered together in terms of their impact on inequalities
in burden of prostate cancer.
Findings in Context of Other Studies
We are not aware of any previous systematic reviews reporting
the international evidence for variations along the continuum
of prostate cancer outcomes by rurality and residential
disadvantage. Our findings were consistent with two earlier
systematic reviews on variations in prostate cancer incidence
and mortality by rurality (5) and survival by socioeconomic
disadvantage (7), respectively. Two earlier reviews also found
persistent geographical disparities across a range of prostate
cancer outcomes in the USA (201) and worldwide (4). None of
these previous reviews critically assessed studies or included the
one-third (58 of 169) of articles included in this review published
since 2014.
Key Gaps in Current Literature and
Suggestions for Future Research
We found only six studies looking at geographical variations in
expectant management (EM) for low-risk disease. Differences
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in use of EM, and the lack of standardized definitions and/or
protocols during the time-periods of the included studies
impaired the comparability across studies. Only one study
(160) specifically distinguished between two main EM strategies
of watchful waiting (palliative treatment for symptomatic
progression) and active surveillance (curative treatment on
evidence of disease progression).
This review highlighted the need for large, high quality
studies that include the whole range of prostate cancer indicators
within the one cohort. It is likely this will require an innovative
combination of population-wide data linkage studies as well
as qualitative investigations. Studies based solely on routinely
collected population-based data, such as cancer registries and/or
hospital separation databases are unable to provide data on
the wide range of patient, tumor, clinician and health-care
system related factors that are likely to be potential confounders.
Collecting information on the characteristics of the geographical
areas, in addition to the characteristics of individuals living in
those areas, combined with more rigorous analytical approaches,
such as multilevel regression (189), will provide greater insights
into the key drivers of this geographical variation.
No studies were found describing geographical differences
in use of relatively new treatments, such as robotic surgery,
management of metastatic prostate cancer, or treatment
making decision processes. It was also unclear whether the
underlying factors contributing to the key patterns in prostate
cancer outcomes are similar for men living in rural and
disadvantaged areas.
Strengths and Limitations
Strengths of this review include the comprehensive search of
current literature over multiple databases for studies describing
international patterns in disparities along the prostate cancer
continuum by rurality and residential disadvantage, quality
checking of all included articles and graphical summary of
results. Given it is now well-recognized that rurality and
residential disadvantage interactively affect cancer outcomes,
rather than acting in isolation (7, 20, 189), we also specifically
assessed the impact of adjusting for residential disadvantage
on variations in all six of considered outcomes by rurality
and vice-versa.
All of the included quantitative studies were observational
in nature, although the majority were population-based cohort
studies. Around half were graded as high quality, none were
graded as low-quality and the majority presented model-
based estimates. Large scale population-based studies are able
to identify associations between geographical measures and
disparities in outcome measures. The challenge is that these
associations in themselves provide only limited information in
terms of the underlying reasons for observed disparities and
hence how they may be reduced.
A key limitation of this review, similar to previous reviews
on similar topics (4, 5, 7) was the wide variability in definition
of rurality and residential disadvantage both within (especially
for the USA) and across countries. For example, area-level
disadvantage was variously defined in terms of a single area-
level indicator (typically income), a study-specific combination
over several area-based measures or a standardized country-
specific composite area-based deprivation index. Moreover,
the concept of rurality itself may differ between countries,
such as Australia (13) and the USA (20) and smaller, more
densely populated, countries, such as the UK (202). The choice
of geographical measure used (20, 61, 130) and the scale
over which it was measured (20, 102, 134, 184) could have
impacted study findings, particularly if, for example, the area-
level effects are only present in the more extreme values of the
remoteness continuum.
Studies also varied widely in their data collection, analytical
and reporting methods, the time frames for both diagnostic
and survival intervals and covariates included in the statistical
analysis. The wide heterogeneity across studies precluded a meta-
analysis and limited their comparability.
Finally, despite searching multiple databases with complex
queries and evaluating reference lists of identified articles, the
possibility that the search term criteria, or choice of literature
databases, could have inadvertently caused the exclusion of
relevant articles remains.
CONCLUSIONS
We found consistent evidence for geographical inequalities
across a range of prostate cancer indicators across diverse
populations, with men from disadvantaged areas facing a higher
prostate cancer burden. Although there was some evidence of
an association between rural residence and a higher prostate
cancer burden, patterns were less consistent. There needs to
be an increased focus on developing more complex research
strategies to identify the key underlying drivers that can then be
incorporated into evidence-based targeted interventions.
Recognizing the variation in the burden caused by prostate
cancer between countries internationally, it is critical to develop
strategies to at least ensure equitable access to adequate health
care for all men within each country. This would ensure that all
male residents of a country have the opportunity to access the
same level of care regardless of where they live. Key priorities
include diagnosing more aggressive disease early, optimizing
informed patient-treatment decision making and providing men
the best possible treatment for their disease regardless of their
residential location. These tasks pose immense challenges to
health providers in each country and will require collaboration
over a range of concerned stakeholders.
Current evidence points to the benefit of considering
health outcomes underpinned by a multi-level continuum
of advantage/disadvantage where resources at an individual,
social and community level serve to enable or inhibit certain
behaviors and systems over a person’s lifetime. Consequently, it
is important to examine key variables including socioeconomic,
psychosocial, cultural, and geographic characteristics in ways
that reflect the complexity of people’s lives. Employing such a
framework will also limit themisleading reliance on the simplistic
rural-urban dichotomy by highlighting the dynamic relationship
between geography and disadvantage in understanding inequity
in the prostate cancer burden.
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